Humira (Adalimumab)

Humira is indicated for a range of adult and pediatric autoimmune disorders where inhibition of tumor necrosis factor‑alpha reduces disease activity.

• Rheumatoid arthritis, including patients with moderate to severe joint inflammation and functional impairment.
• Psoriatic arthritis, characterized by joint pain and skin lesions that respond to TNF‑α blockade.
• Ankylosing spondylitis, a chronic inflammatory disease of the spine and sacroiliac joints.
• Crohn’s disease, for induction and maintenance of remission in moderate to severe gastrointestinal inflammation.
• Ulcerative colitis, to achieve and sustain remission in adults with active disease.
• Plaque psoriasis and hidradenitis suppurativa, for patients with extensive skin involvement not controlled by topical therapies.

• Adalimumab is a fully human monoclonal antibody that selectively binds soluble and membrane‑bound tumor necrosis factor‑alpha (TNF‑α). By occupying the cytokine’s receptor‑binding site, it prevents TNF‑α from interacting with TNF receptors on cell surfaces, thereby inhibiting downstream signaling pathways that drive inflammation, cell recruitment, and tissue damage associated with autoimmune disease. The blockade reduces production of other pro‑inflammatory mediators such as interleukin‑1 and interleukin‑6, contributing to clinical improvement.

Adalimumab may cause a range of adverse reactions, from mild injection‑site symptoms to rare but serious systemic events.

Common

• Injection site pain, redness, or swelling.
• Upper respiratory tract infections such as nasopharyngitis.
• Headache.
• Nausea.
• Rash or mild skin irritation.
• Fatigue or general malaise.
• Low-grade fever.
• Joint pain or arthralgia.
• Mild diarrhea.

Serious

• Serious infections including tuberculosis, bacterial sepsis, or opportunistic fungal infections.
• Reactivation of hepatitis B virus.
• Malignancies such as lymphoma or skin cancers.
• Neurological disorders like demyelinating disease.
• Heart failure exacerbation.
• Hepatic injury or elevated liver enzymes.
• Autoimmune phenomena such as lupus-like syndrome.
• Anaphylaxis or severe hypersensitivity reactions.

When prescribing adalimumab, clinicians consider several safety precautions to minimize risks and ensure appropriate patient selection.

• Screen for latent tuberculosis and treat before initiating therapy.
• Evaluate for active infections; postpone treatment if serious infection is present.
• Assess hepatitis B status and monitor for reactivation during therapy.
• Use caution in patients with a history of demyelinating disorders or congestive heart failure.
• Avoid use during pregnancy unless benefits outweigh potential risks; discuss with obstetrician.
• Monitor complete blood count and liver function tests periodically.
• Counsel patients on proper injection technique and signs of infection.

Adalimumab can interact with other medicines, influencing infection risk or immune response; clinicians should review a patient’s full medication list.

Avoid

• Live vaccines, because immunosuppression may lead to vaccine‑derived infection.
• Concurrent use of other biologic immunosuppressants (e.g., abatacept, rituximab) due to heightened infection risk.

Use with caution

• Conventional disease‑modifying antirheumatic drugs (DMARDs) such as methotrexate, which may increase immunosuppression.
• Antifungal agents (e.g., azoles) that can affect infection susceptibility.
• Interferon‑beta therapy, as combined immunomodulation may alter efficacy.
• Systemic corticosteroids, especially at high doses, which can amplify infection risk.